Haemonetics (HAE) Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025 summary

Portfolio evolution and strategic focus

• Shifted portfolio to 85% core growth-oriented products, driving most revenue and profit.

• Exited whole blood business to focus on high-growth, high-margin segments where leadership is possible.

• Remaining blood center business increasingly overlaps with plasma apheresis, especially in international markets.

• Recent win with Japanese Red Cross validates plasma apheresis offering in a key international market.

Plasma segment performance and outlook

• Plasma remains a key growth engine, with 4%-7% growth guidance for the year, excluding CSL transition.

• Growth driven primarily by new technology adoption and pricing, followed by share gains and volume recovery.

• Competitive landscape sees new therapies as additive, not substitutive, supporting continued demand.

• Customer capacity expansion projects support a 7% CAGR outlook over seven years.

• Share gains and price increases from technology upgrades expected to be main FY26 growth drivers.

CSL transition and financial impact

• CSL revenue contribution is winding down, with no expected contribution in FY26.

• Margin and EPS impact from CSL loss largely mitigated by cost actions and gains elsewhere; FY guidance targets $4.60 EPS.

• Capacity and infrastructure adjusted to align with future demand and share gains.